# GPT-5.2 Review

**Role:** External referee review
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-18T15:49:43.083445
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 15684 in / 4197 out
**Response SHA256:** 9ffb9cbf7301654e

---

## Referee Report: “Does Coverage Create Capacity? Medicaid Postpartum Extensions and the Supply of Maternal Health Providers”

### Summary and contribution
The paper asks a sharp and policy-relevant question: do Medicaid postpartum coverage extensions (60 days → 12 months) induce a supply-side response in maternal health care markets? The authors use staggered adoption across states (2021–2024) and newly released T‑MSIS Provider Spending data to measure (i) postpartum claims (CPT/HCPCS 59430) and (ii) the number of distinct billing providers for postpartum services, plus placebos (antepartum, delivery) and related services (contraception). The main estimator is Callaway & Sant’Anna (2021), with event studies, placebo outcomes, and additional robustness.

Conceptually, this is a potentially publishable topic for a top field journal and possibly a top general-interest journal if the data/identification threats are convincingly handled. However, as written, **internal validity is materially threatened by data quality/reporting artifacts**, and the current robustness results actually reveal a key fragility (balanced panel estimate ≈ 0). This is not necessarily fatal, but it requires a major rework of the empirical strategy and validation of the measurement.

---

# 1. FORMAT CHECK

**Length**
- Appears to be ~30–40 pages in 12pt, 1.5 spacing (main text + appendix), so **meets the 25+ page expectation**.

**References**
- Cites several relevant papers (Callaway & Sant’Anna; Goodman-Bacon; Rambachan & Roth; Daw et al.; Decker; Clemens & Gottlieb; Kozhimannil; Polsky; etc.).
- **Coverage is incomplete** for (i) postpartum extension empirical literature, (ii) maternal health access/provider supply, (iii) Medicaid managed care/encounter-data measurement, and (iv) recent staggered adoption/event-study inference papers beyond CS and RR.

**Prose**
- Major sections are written in paragraphs (good). Bullets appear mainly in Data/Appendix for variable definitions (appropriate).

**Section depth**
- Introduction: many substantive paragraphs (good).
- Institutional background, Data, Empirical Strategy, Results, Discussion: generally meet 3+ paragraph criterion, though parts of “Conceptual Framework” and some subsections are short.

**Figures**
- In LaTeX source, figures are included via `\includegraphics{...}` with captions/notes and described as having CIs/axes. I cannot verify rendering, but nothing suggests missing axes or “empty” figures.

**Tables**
- Tables contain real numbers, standard errors, Ns. No placeholders detected.

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

## (a) Standard errors / inference
- **PASS**: Tables report SEs in parentheses for key estimates (e.g., Table 2 Panel A: (0.1281), etc.). Event-study notes mention bootstrap-based 95% CIs (1,000 iterations).
- One concern: some text reports p-values without consistently reporting corresponding SEs/CIs in the same place, but the tables do have SEs.

## (b) Significance testing
- **PASS**, but execution could be strengthened:
  - You use chi-squared tests for pretrends and placebo outcomes; good.
  - Randomization inference (RI) is used, but its relationship to the main inference is unclear (see below).

## (c) Confidence intervals
- Event studies have 95% pointwise CIs (good).
- **Main tables do not report 95% CIs**, only SEs and stars. For a top journal, I recommend adding **95% CIs for all main outcomes**, at least in notes or an additional column/panel.

## (d) Sample sizes
- Regression Ns are reported as “State-months = 4284” etc. **PASS**.

## (e) DiD with staggered adoption
- **PASS on estimator choice**: you use Callaway & Sant’Anna with not-yet-treated as controls, and cite Goodman-Bacon.
- **But**: you also present TWFE as robustness; fine, but you should be clearer that TWFE is not a valid robustness check unless you show that the identifying assumptions imply TWFE is approximately unbiased (e.g., homogeneous effects, or no negative weights problems). Right now TWFE attenuation is used as “expected,” but TWFE could differ for many reasons.

## (f) Other inference issues that need attention (important)
1. **Small number of control units / few never-treated states**
   - Effective “never-treated” pool is tiny (AR, WI, plus “not-yet-treated” ID/IA coded never-treated). With 51 clusters, clustered SEs are fine for TWFE, but **CS-DiD’s uncertainty with few effective comparison units can be substantial**, and bootstrap procedures may understate uncertainty depending on how resampling is done.
   - The paper’s own RI suggests weak rejection (p = 0.21). You need to reconcile: **why is the conventional p-value 0.027 while RI says 0.21?** This discrepancy is a red flag unless clearly explained (e.g., different nulls, different assignment mechanism, weak power given small number of states, etc.).

2. **Clustering / serial correlation**
   - For TWFE you cluster by state (good). For CS-DiD, you mention bootstrap iterations, but not the bootstrap scheme. You should specify whether you use **state-level block bootstrap** (resample states) vs. naive observation-level bootstrap, and justify it. With state-month panels, inference must respect within-state serial correlation.

3. **Log(Claims + 1) with zeros and suppression**
   - You use `log(y+1)` and also acknowledge **cell suppression below 12 claims** in the data appendix, plus “intermittent reporting.”
   - This is not a cosmetic issue: suppression + intermittent reporting mechanically creates zeros or missingness that can change with reporting practices. This is likely central to the balanced-panel collapse.

**Bottom line on methodology:** you use modern DiD tools, but **the inference and measurement process need to be made substantially more credible and transparent** for publication.

---

# 3. IDENTIFICATION STRATEGY

## What works well
- Clear statement of identification (parallel trends) and direct use of event studies.
- Placebo outcomes (antepartum, delivery) are well-chosen and conceptually persuasive.
- HonestDiD sensitivity analysis is a plus and candidly discussed.

## Major threat (currently not resolved): data/reporting confounding
The paper itself identifies the key problem:

> Balanced panel restriction … produces an attenuated estimate of 0.0028 … much of the variation comes from states with intermittent T‑MSIS reporting.

This is **not a minor limitation**; it threatens the core claim that the policy caused the observed increase. If “treatment” correlates with improvements in encounter/claims reporting or changes in suppression/missingness, then:
- claims counts can rise mechanically even without any utilization/provider response;
- the number of “distinct providers billing code 59430” can rise mechanically if previously unreported claims become reported;
- placebo tests may not detect it if reporting improvements are code-specific (e.g., postpartum visit coding practices change) rather than broad.

### What you need to do to restore credibility
1. **Demonstrate stable measurement of the outcome in the pre-period within each state.**
   - Show, by state, the fraction of months with zero postpartum claims and how that changes around adoption.
   - Show whether “zeros” are true zeros vs. suppression/missingness artifacts. If suppressed cells are dropped, are you coding them as 0? This must be explicit.

2. **Exploit alternative outcomes less sensitive to reporting**
   - Payments ($) rather than claim counts (if payments are less suppressed or less intermittently missing).
   - Beneficiary counts.
   - Broader postpartum-related code baskets (to reduce “coding idiosyncrasy” of 59430).
   - Outcomes at higher aggregation (e.g., all postpartum-related E/M visits) to reduce suppression.

3. **Use a design that differences out reporting quality**
   - Your DDD postpartum vs antepartum is a good idea, but currently implemented only as TWFE and is imprecise.
   - Consider implementing **CS-DiD-style** estimands for DDD (e.g., stack the two outcomes and estimate an interacted model with appropriate group-time aggregation, or use “ratio”/difference outcomes at the state-month level: log(postpartum) − log(antepartum) where feasible).
   - Or use a **negative control code family** similar in frequency/suppression risk to postpartum code 59430 but unaffected by the policy.

4. **Policy endogeneity**
   - Adoption timing correlates with Medicaid capacity/politics (you note this). Event-study pretrends help, but if reporting improvements occur *at adoption* due to administrative modernization associated with the SPA, pretrends may still look fine.
   - You should test for changes in **overall T‑MSIS volume** (all claims) and in claims for unrelated common codes at adoption.

5. **PHE overlap**
   - You motivate PHE as “non-binding” early on. But the end of PHE and unwinding is a massive administrative shock that could differentially affect claim volumes/reporting across states.
   - Your post-PHE restriction is helpful, but you should more sharply center identification on this window (or treat April 2023 as an additional policy interaction).

**Conclusions vs. evidence**
- The current headline (“extensions increased claims 33% and providers 12%”) is too strong given the balanced-panel near-zero estimate and RI p=0.21. The paper is more accurately described as: *suggestive evidence of increased postpartum billing in the full sample, but estimates are sensitive to data quality and inference choices.*

**Limitations**
- You do discuss limitations, but given the balanced-panel result, the “data quality varies” point needs to be elevated from limitation to **core identification challenge with a proposed resolution**.

---

# 4. LITERATURE (missing references + BibTeX)

## (i) Staggered DiD / event-study methods beyond CS
You cite CS, Goodman-Bacon, Rambachan-Roth. Consider adding:
- Sun & Abraham (2021) for heterogeneous treatment effects event studies.
- Borusyak, Jaravel & Spiess (2021) on imputation/efficient DiD with staggered adoption.
- de Chaisemartin & D’Haultfoeuille (2020/2022) on TWFE with heterogeneity.

```bibtex
@article{SunAbraham2021,
  author = {Sun, Liyang and Abraham, Sarah},
  title = {Estimating Dynamic Treatment Effects in Event Studies with Heterogeneous Treatment Effects},
  journal = {Journal of Econometrics},
  year = {2021},
  volume = {225},
  number = {2},
  pages = {175--199}
}

@article{BorusyakJaravelSpiess2021,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, Jann},
  title = {Revisiting Event Study Designs: Robust and Efficient Estimation},
  journal = {arXiv preprint arXiv:2108.12419},
  year = {2021}
}

@article{deChaisemartinDhaul2020,
  author = {de Chaisemartin, Cl{\'e}ment and D'Haultf{\oe}uille, Xavier},
  title = {Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects},
  journal = {American Economic Review},
  year = {2020},
  volume = {110},
  number = {9},
  pages = {2964--2996}
}
```

(If you prefer only peer-reviewed citations, keep Sun-Abraham and de Chaisemartin–D’Haultfoeuille; BJS is widely cited but originally circulated as a working paper.)

## (ii) Medicaid postpartum extension empirical literature
The paper cites Gordon (2023), Daw (2021), McMorrow (2020), but postpartum extension evidence has grown quickly (ASPE, Health Affairs, JAMA/NEJM Catalyst, etc.). At minimum, cite work on postpartum extension effects on coverage/utilization and maternal health disparities to position your novelty as *provider supply*.

Examples to consider (please verify exact bibliographic details and choose the closest):
```bibtex
@article{Gordon2023,
  author = {Gordon, Sherri and Sommers, Benjamin D. and others},
  title = {Medicaid Postpartum Coverage Extension and Maternal Health Care Use},
  journal = {Health Affairs},
  year = {2023},
  volume = {42},
  number = {X},
  pages = {XXX--XXX}
}
```
(You already cite Gordon 2023 but the bib entry should be complete; I can’t infer exact issue/pages from the LaTeX.)

Also consider citing policy/evidence syntheses:
```bibtex
@techreport{ASPE2022Postpartum,
  author = {{Office of the Assistant Secretary for Planning and Evaluation}},
  title = {Medicaid Postpartum Coverage Extension: Early Evidence and Considerations},
  institution = {U.S. Department of Health and Human Services},
  year = {2022}
}
```

## (iii) Medicaid claims/encounter data quality (crucial for *your* identification)
You cite MACPAC (2022) generally. You should add methodological references on T‑MSIS quality/validity and encounter-data completeness, because your main threat is reporting:

```bibtex
@techreport{MACPAC2024TMSIS,
  author = {{Medicaid and CHIP Payment and Access Commission}},
  title = {T-MSIS Data Quality and Use for Analytic Purposes},
  institution = {MACPAC},
  year = {2024}
}
```

(Again, fill in the exact title/year/report number you use—there are multiple MACPAC/CMS documents on T‑MSIS quality.)

## (iv) Provider participation in Medicaid
You cite Decker (2012), Clemens (2014/2017), Polsky (2015). Also consider classic Medicaid fee/billing participation work (e.g., Currie & Gruber on Medicaid expansions; though older and demand-side, it’s canonical) and more recent papers on provider networks/participation responses to payment changes.

```bibtex
@article{CurrieGruber1996,
  author = {Currie, Janet and Gruber, Jonathan},
  title = {Health Insurance Eligibility, Utilization of Medical Care, and Child Health},
  journal = {Quarterly Journal of Economics},
  year = {1996},
  volume = {111},
  number = {2},
  pages = {431--466}
}
```

---

# 5. WRITING QUALITY (CRITICAL)

## (a) Prose vs bullets
- **PASS**. The paper is largely well written in paragraph form.

## (b) Narrative flow
- Strong motivation and clear statement of the gap (“supply-side response”).
- The PHE discussion is useful, but the narrative currently over-promises “clean placebo period” while later results show serious measurement issues. I recommend reframing earlier to acknowledge that **administrative data artifacts are first-order**.

## (c) Sentence quality / clarity
- Generally crisp and readable.
- A few places would benefit from tightening and consistency:
  - You alternate between “provider supply,” “providers billing,” “provider participation.” These are distinct concepts; define them carefully and stick to one framing (e.g., “billing participation” as measured).

## (d) Accessibility / magnitudes
- Good effort to interpret log points as percentages.
- The calculation translating to “0.03 additional postpartum claims per Medicaid birth” is helpful but may confuse readers because the unit of analysis is state-month; I’d recommend a clearer utilization metric (e.g., postpartum visit rate per 100 births) if you can construct a denominator from delivery codes within T-MSIS.

## (e) Tables
- Tables are clear with notes. One improvement: explicitly add **95% CIs** and clarify the inference method for CS-DiD (bootstrap type, clustering).

---

# 6. CONSTRUCTIVE SUGGESTIONS (to increase impact and credibility)

## A. Make data validity a central, testable component
Given the balanced-panel result, the paper needs a dedicated “Data validity / reporting” section with concrete diagnostics:
1. State-by-state completeness measures over time (share of months with suppressed/zero postpartum claims; total claims volume).
2. Compare trends in *all* claims (or common codes) around adoption to detect reporting jumps.
3. Show whether adoption correlates with changes in managed care encounter submission (a known issue).

## B. Strengthen the outcome design
1. Replace or supplement 59430 with a **basket of postpartum-related codes** (postpartum E/M visits, depression screening, hypertension follow-up, etc.), pre-specified and clinically grounded. A single code is fragile.
2. Construct **rates**: postpartum claims per delivery claims (from delivery CPT codes) at the state-month level. This may partially difference out reporting shocks affecting all obstetric claims similarly.

## C. Improve identification around PHE unwinding
A promising angle is to exploit bindingness explicitly:
- Estimate effects separately for adopters whose extension became effective **after** April 2023 vs before.
- Or interact treatment with an indicator for post-April-2023: effect should be ~0 during PHE if non-binding, then rise after PHE end. This is a sharp, testable prediction and can serve as an internal validity check.

## D. Reconcile inference (conventional vs RI) and use appropriate small-sample methods
- Clarify the assignment mechanism for RI (what is being permuted—cohort timing? treated vs untreated?).
- Consider **wild cluster bootstrap** for TWFE and/or cluster-robust bootstrap by state for CS-DiD.
- Given few “never treated,” consider estimators/settings that do not lean heavily on the never-treated group (e.g., not-yet-treated only, careful trimming of late periods).

## E. Provider “supply” interpretation
Right now, “provider supply” = “distinct NPIs billing 59430.” That is closer to *billing participation for one code* than capacity. Consider:
- Distinct NPIs billing **any postpartum-related codes**.
- Total postpartum claims per postpartum provider (intensive vs extensive decomposition).
- If possible, separate individual NPIs vs organizational NPIs (NPPES entity type) to avoid counting facility billing NPIs as “providers.”

---

# 7. OVERALL ASSESSMENT

## Key strengths
- Important and under-studied question: supply-side response to coverage duration.
- Novel data source with potentially high value for the literature.
- Uses modern staggered DiD (CS) and includes event studies, placebos, and sensitivity analysis.
- Clear writing and strong policy motivation.

## Critical weaknesses (must be addressed)
1. **Internal validity threatened by T‑MSIS reporting/intermittency**; balanced-panel restriction collapses the estimate to ~0, suggesting the headline result may be driven by reporting artifacts rather than behavior.
2. **Inference is not yet fully credible/transparent**: bootstrap scheme for CS-DiD is underspecified; RI contradicts conventional inference; few effective controls.
3. “Provider supply” is operationalized narrowly and may overstate real capacity effects.

## Path to improvement
- Elevate data quality to a core identification problem and resolve it with diagnostics and redesigned outcomes (rates/baskets/payments).
- Re-center the design on the post-PHE period and/or bindingness interaction.
- Provide robust inference aligned with the panel structure and small effective control group.

DECISION: MAJOR REVISION